VERTEX PHARMACEUTICALS INC / MA Cash
VERTEX PHARMACEUTICALS INC / MA (VRTX) had Cash of $3.30 billion as of 2023-12-31, per its 10-K filed 2024-02-15.
Discontinued › Balance Sheet › Assets › Cash, Cash Equivalents, and Short-Term Investments › Cash and Cash Equivalent
us-gaap:Cash · last filed 2024-02-15
- 2023-12-31: Cash $3.30B.
- 2023-09-30: Cash $5.50B.
- 2023-06-30: Cash $4.20B.
- 2023-03-31: Cash $2.10B.
| Period end | Cash |
|---|---|
| 2023-12-31 | $3.30B 10-K · filed 2024-02-15 |
| 2023-09-30 | $5.50B 10-Q · filed 2023-11-07 |
| 2023-06-30 | $4.20B 10-Q · filed 2023-08-02 |
| 2023-03-31 | $2.10B 10-Q · filed 2023-05-02 |
| 2022-12-31 | $3.10B 10-K · filed 2024-02-15 |
| 2022-09-30 | $3.50B 10-Q · filed 2022-10-28 |
| 2022-06-30 | $3.50B 10-Q · filed 2022-08-05 |
| 2022-03-31 | $3.20B 10-Q · filed 2022-05-06 |
| 2021-12-31 | $3.30B 10-K · filed 2023-02-10 |
| 2021-09-30 | $2.70B 10-Q · filed 2021-11-03 |
| 2021-06-30 | $2.40B 10-Q · filed 2021-07-30 |
| 2021-03-31 | $2.40B 10-Q · filed 2021-04-30 |
| 2020-12-31 | $2.80B 10-K · filed 2022-02-09 |
| 2020-09-30 | $2.20B 10-Q · filed 2020-10-30 |
| 2020-06-30 | $2.30B 10-Q · filed 2020-07-31 |
| 2020-03-31 | $1.80B 10-Q · filed 2020-05-01 |
| 2019-12-31 | $2.30B 10-K · filed 2021-02-11 |
| 2019-09-30 | $1.90B 10-Q · filed 2019-10-31 |
| 2019-06-30 | $1.70B 10-Q · filed 2019-08-01 |
| 2019-03-31 | $1.50B 10-Q · filed 2019-05-01 |
| 2018-12-31 | $1.40B 10-K · filed 2020-02-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |